Stocksigma LogoStocksigma Logo

Beta Drugs Reports Strong H1 FY27 Performance with 45% PAT Growth

Beta Drugs posted 29.2% YoY revenue growth for H1 FY27, with PAT rising ~45% YoY to INR34 crores and EBITDA margins at 23.18%

Beta Drugs Reports Strong H1 FY27 Performance with 45% PAT Growth

Beta Drugs Ltd · Transcript · 28 Oct 2026, 10:27 pm

Beta Drugs Reports Strong H1 FY27 Performance with 45% PAT Growth Beta Drugs posted 29.2% YoY revenue growth for H1 FY27, with PAT rising ~45% YoY to INR34 crores and EBITDA margins at 23.18%. Management noted zero material impact from NPPA trade margin capping. Nivian Lifesciences grew 75% YoY to INR31 crores, while the API segment expanded 29% YoY, supported by an upcoming intermediate plant operational by Jan'27. Management reaffirmed medium-term revenue growth guidance of 20%–25% with 23%–24% sustained EBITDA margins, targeting INR150 crores in own-brand sales and INR90–100 crores in exports for FY27.

Original exchange filing (PDF)

More announcements from Beta Drugs Ltd

All Beta Drugs Ltd announcements